  For the past twelve years, cold plasmas have been positioned as a
breakthrough technology for treating cancer thanks to their antitumor
properties. The innovation of ad hoc plasma sources and personalized protocols
appears crucial to treat cancers with a very poor prognosis. This is the case
for cholangiocarcinoma (CCA) , whose treatment with cold plasma requires the
innovation of catheters and endoscopic devices for local therapies. Before
conducting clinical trials, the performances and limitations of cold plasma
endoscopy must be evaluated in terms of safety for both the patient and
clinician as well as in terms of therapeutic efficacy. These objectives are
pursued in the present work, in which a transferred plasma catheter is used,
powered by 8-10 kV, 5-10 kHz repeated pulses, allowing guided streamers to be
transferred over lengths of at least 2 m. In a first step, the catheter is
directly inserted into an artificial model reproducing the topography and the
electrical response of the biliary tree. This model allows to validate the
technical feasibility of the technology and to demonstrate the absence of
electrical and thermal risks. In a second step, the catheter is inserted into
the duodenoscope, the whole being applied to a porcine anatomical model. After
passing through the esophagus, stomach and duodenum, the distal part of the
duodenoscope is placed at the entrance to the papilla so that the catheter can
easily enter the choledoc and then the common bile duct. Interestingly, the
electrical power values deposited are of the order of 100 mW especially because
the current values are at least 10 times higher. The absence of electrical and
thermal risks is demonstrated and consolidated by the IEC standards for medical
devices. In a third time, we demonstrate that the cold plasma catheter can
induce antitumor effects on in vitro experimental models of human CCA.
